Newsfeeds - Spark Newswire

1 minute read

Pre-Market Outlook

Benzinga Pro’s Top 5 Stocks To Watch For Monday, Aug. 16, 2021: MGI, ENLV, GNUS, PCG, FATE

August 16, 8:57 AM

Today's 5 Stock Ideas: MoneyGram (MGI) - Company CEO, Alexander Holmes, will interview on Benzinga's "Power Hour" YouTube show at 12:30 p.m. EDT Monday. Enlivex Therapeutics

ENLV

3 minute read

The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow

By Shanthi Rexaline

August 15, 11:05 AM

Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among those reporting during the week.

ABSI

1 minute read

Cathie Wood’s ARK Invest Posts Fund Purchases For Wednesday, Aug. 11, 2021: DKNG, ETSY, Z, SMFR, SRNG, PATH, NTLA, BLI, TSP, FATE, VCYT, SGFY, MKFG, SPFR, VUZI, LPSN, BLDE

By Michael Horton

August 12, 9:27 AM

DraftKings (DKNG) - 91,300 Shares Etsy (ETSY) - 9,700 Shares Zillow Group (Z) - 115,352 Sema4 (SMFR) - 148,073 Soaring Eagle Acquisition (SRNG) - 90,000 UiPath (PATH) - 22,717 Intellia Therapeutics (NTLA) -

BLDE

1 minute read

Cathie Wood’s ARK Invest Posts Fund Purchases For Tuesday, Aug. 10, 2021: DKNG, ETSY, ADPT, BEAM, SMFR, SGFY, PATH, SRNG, TSP, FATE, Z, VUZI, SPFR, MKFG, LPSN, BLDE, KTOS

By Michael Horton

August 11, 10:15 AM

DraftKings (DKNG) - 35,900 Shares Etsy (ETSY) - 8,800 Adaptive Biotechnologies (ADPT) - 268,463 Beam Therapeutics (BEAM) - 48,616 Sema4 (SMFR) - 201,832 Signify Health (SGFY) - 308,074 UiPath (PATH) -

ADPT

1 minute read

SVB Leerink Maintains Outperform on Fate Therapeutics, Lowers Price Target to $118

By Benzinga Newsdesk

August 5, 6:57 AM

SVB Leerink analyst Daina Graybosch maintains Fate Therapeutics (NASDAQ:FATE) with a Outperform and lowers the price target from $120 to $118.

FATE

1 minute read

HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $121

By Benzinga Newsdesk

August 5, 6:51 AM

HC Wainwright & Co. analyst Robert Burns maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and raises the price target from $120 to $121.

FATE

1 minute read

Fate Therapeutics Q2 EPS $(0.58) Misses $(0.53) Estimate, Sales $13.41M Up From $5.46M YoY

By Benzinga Newsdesk

August 4, 4:41 PM

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.53) by 9.43 percent. This is a 65.71 percent decrease over losses of $(0.35) per share

FATE

6 minute read

The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings

By Shanthi Rexaline

August 4, 7:52 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3)

ABSI

24 minute read

Earnings Scheduled For August 4, 2021

By Benzinga Insights

August 4, 4:10 AM

Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.

ABC

4 minute read

FDA
News

Fate Therapeutics Reports Treatment Of First Patient In Phase 1 Trial Of FT819

By Benzinga Newsdesk

August 2, 4:50 PM

Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate Three Dosing Regimens of FT819 for

FATE